Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI
Authors:
- 30 June 2018
- journal article
- review article
- Published by Springer Nature in Infection
- Vol. 46 (5) , 599-605
Abstract
Here, we report the case of an HIV positive patient under a dual antiretroviral drug regimen with tenofovir disoproxil and darunavir/ritonavir with stable clinical, virological, and immunological response over 126 weeks. Dual antiretroviral therapy has the advantage of reduced toxicity and lower health care costs, treatment failure and fostering drug resistance are perceived risks. Optimal drug combinations and indication criteria for dual treatment remain controversial. Nevertheless, first clinical trials indicate non-inferiority for combinations of nucleoside reverse transcriptase inhibitors and protease inhibitors. This case presents the combination of tenofovir disoproxil in combination with a protease inhibitor as a new potential dual treatment regimen.Keywords
Funding Information
- BMBF (03ZZ0820D, 01KI1501)
This publication has 23 references indexed in Scilit:
- Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trialThe Lancet Infectious Diseases, 2014
- Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D StudyaThe Journal of Infectious Diseases, 2013
- Update on tenofovir toxicity in the kidneyPediatric Nephrology, 2012
- A Randomized, Open-Label Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor-Sparing Regimen in Antiretroviral-Naive HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot studyHIV Medicine, 2008
- Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)AIDS, 2006
- Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug‐Resistant HIV‐1 InfectionClinical Infectious Diseases, 2005
- Evaluation of Safety and Efficacy of 3TC (Lamivudine) in Patients with Asymptomatic or Mildly Symptomatic Human Immunodeficiency Virus Infection: A Phase I/II StudyThe Journal of Infectious Diseases, 1995
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986